Budget 2018-19

  The risk of blood clots is higher after infection with the SARS-CoV-2 virus than after immunisation with Pfizer and AstraZeneca Covid-19 vaccines, according to a study The risk of developing adverse events such as blood clots is considerably higher after infection with the SARS-CoV-2 virus than after immunisation with Pfizer and AstraZeneca COVID-19 vaccines, according to a large UK study published in the British Medical Journal (BMJ) on Friday. The team led by researchers at the University of Oxford in the UK conducted the study on thrombocytopenia — a condition with low platelet counts — and thromboembolic events or blood clots following COVID-19 vaccination with  Oxford-AstraZeneca  and Pfizer-BioNTech preventives. Some of these events have led to restricted use of the Oxford-AstraZeneca vaccine, known as Covishield in India, in a number of countries. The researchers compared rates of adverse events after vaccination with rates of the same events after a positive SAR...

  Brazil made a diplomatic push to guarantee an Indian-made shipment of British drugmaker AstraZeneca’s Covid-19 vaccine, hoping to avoid export restrictions that could delay immunisations BRASILIA/RIO DE JANEIRO (Reuters) – Brazil made a diplomatic push on Monday to guarantee an Indian-made shipment of British drugmaker AstraZeneca’s COVID-19 vaccine, hoping to avoid export restrictions that could delay immunizations during the world’s second-deadliest outbreak. In parallel, Brazil’s private clinics struck a preliminary deal for an alternative injection made by India’s Bharat Biotech despite a lack of public results from late-stage trials. The scramble by Brazil’s government and private sector underscored how Latin America’s largest nation, once an example of mass immunization success in the developing world, has fallen behind peers in the race to inoculate against the coronavirus. Plans by Brazil’s Fiocruz Institute to import  AstraZeneca’s vaccine  in bulk, filling and...